ATS 2022
Treating Severe Eosinophilic Asthma: Mepolizumab vs Benralizumab
What is the difference in efficacy between mepolizumab and benralizumab, 2 biologics approved for the treatment of severe eosinophilic asthma?
Your search for mepolizumab returned 56 results
AAAAI 2022
Mepolizumab Improves Loss of Smell in Chronic Rhinosinusitis With Nasal Polyps
The phase 3 SYNAPSE clinical trial evaluated the efficacy of mepolizumab in improving sense of smell in patients with chronic rhinosinusitis with nasal polyps.
AAAAI 2021, News
Mepolizumab Improves Symptoms in Chronic Rhinosinusitis With Nasal Polyps
Mepolizumab reduces disease symptoms in patients with chronic rhinosinusitis with nasal polyps, according to the results of a randomized, double-blind, multicenter study.
Drugs in the Pipeline
Mepolizumab Gets Priority Review for Hypereosinophilic Syndrome
The FDA previously granted Fast Track and Orphan Drug designations to mepolizumab for the treatment of HES.
ATS 2020
Discontinuing Mepolizumab Decreases Asthma Control, Increases Eosinophil Counts
Patients with severe eosinophilic asthma who are treated with mepolizumab and subsequently stop treatment have increased blood eosinophil counts and increased exacerbations, among other negative clinical outcomes.
ATS 2020
Discontinuing Mepolizumab Decreases Asthma Control, Increases Eosinophil Counts
Patients with severe eosinophilic asthma who are treated with mepolizumab and subsequently stop treatment have increased blood eosinophil counts and increased exacerbations, among other negative clinical outcomes.
AAAAI 2020, News
Mepolizumab Improves QoL in Severe Asthma and Nasal Polyps, Allergic Rhinitis
Treatment with mepolizumab is associated with improvements in asthma exacerbation rates and health-related quality of life in patients with severe eosinophilic asthma and comorbid nasal polyps, sinusitis, or allergic rhinitis.
Drugs in the Pipeline
Mepolizumab Reduces Flares in Patients With Hypereosinophilic Syndrome
GlaxoSmithKline announced positive results from the pivotal phase 3 study of mepolizumab in the treatment of patients with hypereosinophilic syndrome (HES). HES is a rare group of inflammatory disorders characterized by persistent eosinophilia that can potentially lead to inflammation, organ damage, and possibly death if left untreated. The 32-week, double-blind, placebo-controlled phase 3 study evaluated…
ACAAI 2019, News
Mepolizumab Reduced Eosinophils, Exacerbations in Severe Eosinophilic Asthma
Mepolizumab was associated with reductions in eosinophil levels and asthma exacerbations,
as well as improvements in quality of life in uncontrolled severe eosinophilic asthma.
ACAAI 2019, News
Mepolizumab Significantly Reduces Asthma Exacerbations and Associated Costs
In a real-world setting, mepolizumab therapy significantly reduced the rate of asthma exacerbations and their related costs.
